Effects of Ferulic Acid and Angelica archangelica Extract (Feru-guard ®) on Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Prospective Trial

Chiaki Kudoh; Tomokatsu Hori; Shunji Yasaki; Ryu Ubagai; Takeshi Tabira

doi:10.3233/ADR-200211

Effects of Ferulic Acid and Angelica archangelica Extract (Feru-guard^®) on Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Prospective Trial

J Alzheimers Dis Rep. 2020 Sep 18;4(1):393-398. doi: 10.3233/ADR-200211.

Authors

Chiaki Kudoh¹, Tomokatsu Hori², Shunji Yasaki³, Ryu Ubagai², Takeshi Tabira^{1

4}

Affiliations

¹ Kudoh Clinic for Neurosurgery & Neurology, Ota-ku, Tokyo, Japan.
² Moriyama Neurological Center Hospital, Edogawa-ku, Tokyo, Japan.
³ Department of Neurology, Shin-Yurigaoka General Hospital, Furusawa, Aso-ku, Kawasaki, Japan.
⁴ Department of Diagnosis, Prevention and Treatment of Dementia, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.

Abstract

We conducted a multicenter, randomized, double-blind, placebo-controlled prospective trial examining a supplement containing ferulic acid and Angelica archangelica extract (Feru-guard^®) for mild cognitive impairment (MCI). In the intention-to-treat population, Mini-Mental State Examination (MMSE) scores were significantly better at 24 weeks (p = 0.041) in the active group. In the per protocol population, MMSE was significantly better in the active group at 24 weeks (p = 0.008), and mixed effect models for repeated measures (MMRM) showed significant difference (p = 0.016). ADAS-Jcog was significantly better at 24 (p = 0.035) and 48 weeks (p = 0.015) in the active group, and MMRM was significant (p = 0.031). Thus, Feru-guard^® may be useful for MCI.

Keywords: Angelica archangelica; dementia; dietary supplement; double-blind randomized trial; ferulic acid; mild cognitive impairment.